Scientific article

Nouvelles thérapies en rhumatologie pédiatrique

Published inRevue médicale suisse, vol. 8, no. 329, p. 418-422
Publication date2012

Biotherapies are recent treatments, which target molecules implicated in the pathogenesis of inflammatory diseases. In pediatric rheumatology, we use anti-TNF-alpha and abatacept in JIA patients with polyarticular involvement, whereas anti-IL-6 and anti-IL-1 blockers are efficacious in the systemic form of JIA and other auto-inflammatory conditions. These new treatments have significantly improved the control of articular and systemic inflammation and the prognosis of rheumatic diseases. Their effect and their safety on the long-term need to be assessed on large cohorts of patients. Due to the impact of these chronic illnesses on the young patient and its family, and the required specific knowledge, the care of these children should be provided by a multidisciplinary team linked to a centre of competence.

  • Biological Agents/therapeutic use
  • Child
  • Humans
  • Rheumatic Diseases/drug therapy
Citation (ISO format)
ENDERS, Felicitas Bellutti et al. Nouvelles thérapies en rhumatologie pédiatrique. In: Revue médicale suisse, 2012, vol. 8, n° 329, p. 418–422.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation10/08/2013 11:53:00 AM
First validation10/08/2013 11:53:00 AM
Update time03/14/2023 8:38:25 PM
Status update03/14/2023 8:38:25 PM
Last indexation01/16/2024 8:15:10 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack